The Cerebral Edema drugs in development market research report provides comprehensive information on the therapeutics under development for Cerebral Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Cerebral Edema. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Cerebral Edema and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Cerebral Edema by ten companies/universities/institutes. The top development phase for Cerebral Edema is preclinical with five drugs in that stage. The Cerebral Edema pipeline has nine drugs in development by companies and two by universities/ institutes. Some of the companies in the Cerebral Edema pipeline products market are: University of Arizona, Curatis and Chengdu Jinrui Foundation Biotechnology.
The key targets in the Cerebral Edema pipeline products market include Aquaporin 4, ATP Binding Cassette Sub Family C Member 8, and Calmodulin.
The key mechanisms of action in the Cerebral Edema pipeline product include Aquaporin 4 Blocker with two drugs in Phase I. The Cerebral Edema pipeline products include four routes of administration with the top ROA being Intramuscular and two key molecule types in the Cerebral Edema pipeline products market including Small Molecule, and Monoclonal Antibody.
Cerebral Edema overview
Cerebral edema is excess accumulation of fluid (edema) in the intracellular or extracellular spaces of the brain. This causes impaired nerve function, increased pressure within the skull, and can eventually lead to direct compression of brain tissue and blood vessels. Symptoms vary based on the location and extent of edema and generally include headaches, nausea, vomiting, seizures, drowsiness, visual disturbances, dizziness, and in severe cases, death.
For a complete picture of Cerebral Edema’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
